Je-Ho Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Je-Ho Lee has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Dojin Kim
Molecular Therapy Research Center, Sungkyunkwan University, Samsung Medical Center Annex 8F, Kangnam-ku, Seoul, Korea
1 shared publicationJinhee Park
Molecular Therapy Research Center, Sungkyunkwan University, Samsung Medical Center Annex 8F, Kangnam-ku, Seoul, Korea
1 shared publicationKwangbae Kim
Molecular Therapy Research Center, Sungkyunkwan University, Samsung Medical Center Annex 8F, Kangnam-ku, Seoul, Korea
1 shared publicationKyoungsook Park
Molecular Therapy Research Center, Sungkyunkwan University, Samsung Medical Center Annex 8F, 50 Ilwon-dong, Kangnam-ku, Seoul 135-710, Korea
1 shared publicationKyusam Choi
Molecular Therapy Research Center, Sungkyunkwan University, Samsung Medical Center Annex 8F, Kangnam-ku, Seoul, Korea
1 shared publicationSeung Bae Rho
Molecular Therapy Research Center, Sungkyunkwan University, Samsung Medical Center Annex 8F, Kangnam-ku, Seoul, Korea
1 shared publication
Latest Publications
- Open Access
- 1 February 2005
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 65 (3) , 749-757
Homeobox Msx1 Interacts with p53 Tumor Suppressor and Inhibits Tumor Growth by Inducing Apoptosis
The stability of wild-type p53 is critical for its apoptotic function. In some cancers, wild-type p53 is inactivated by interaction with viral and cellular proteins, and restoration of its activity has therapeutic potential. Here, we identify homeobox Msx1 as a p53-interacting protein and show its novel function as a p53 regulator. Overexpression of homeobox Msx1 induced apoptosis of cancer cells harboring nonfunctional wild-type p53 and suppressed growth of human tumor xenografts in nude mice. The homeodomain of Msx1 functions as a protein-protein interacting motif rather than a DNA-binding domain and is essential for stabilization, nuclear accumulation, and apoptotic function of wild-type p53. The identification of a novel function of Msx1 as a p53 regulator may open new avenues for developing improved molecular therapies for tumors with a nonmutational p53 inactivation mechanism.
- 1 February 2005
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 65 (3) , 749-757
Open AccessHomeobox Msx1 Interacts with p53 Tumor Suppressor and Inhibits Tumor Growth by Inducing Apoptosis
The stability of wild-type p53 is critical for its apoptotic function. In some cancers, wild-type p53 is inactivated by interaction with viral and cellular proteins, and restoration of its activity has therapeutic potential. Here, we identify homeobox Msx1 as a p53-interacting protein and show its novel function as a p53 regulator. Overexpression of homeobox Msx1 induced apoptosis of cancer cells harboring nonfunctional wild-type p53 and suppressed growth of human tumor xenografts in nude mice. The homeodomain of Msx1 functions as a protein-protein interacting motif rather than a DNA-binding domain and is essential for stabilization, nuclear accumulation, and apoptotic function of wild-type p53. The identification of a novel function of Msx1 as a p53 regulator may open new avenues for developing improved molecular therapies for tumors with a nonmutational p53 inactivation mechanism.